CA9 and breast carcinoma: Furthermore, recent evaluation of soluble CAIX (sCAIX) induced by shedding in breast cancer patients treated with bevacizumab showed that sCAIX levels are predictive of therapeutic response to inhibition of angiogenesis [30].